Caplyta Hits Its Goal in a Phase 3 Bipolar Mania Trial
CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins85% CONFIDENCEOverall confidence: 85%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or betterThe release is datelined "TITUSVILLE, N.J. (September 21, 2026) - Johnson & Johnson (NYSE: JNJ[1][4]) today announced positive topline results from the pivotal Phase 3 study", and its PR Newswire copy is timestamped "Sep 21, 2026, 08:00 ET" (12:00 UTC).
Johnson & Johnson reported positive topline results from Study 451: once-daily Caplyta (lumateperone) 42 mg cut manic symptoms in bipolar I disorder by 4.8 YMRS points more than placebo at week 3, with a significant effect from day 3.